Tirofiban
Tandem Occlusion
Xueli CaiSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Tandem Occlusion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tbo-309 ThromBio Pty. Ltd. | Phase 2 | CCC |
Acetylsalicylic Acid The Second Hospital of Anhui Medical University | N/A | D |
Same molecule, other indications
Tirofiban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →